Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Criterium, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1991-01-01

Employees: 101

Market Cap: -

Website: http://www.criteriuminc.com

Clinical Trials

Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer

Phase 2

Not yet recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Fruquintinib+ Lonsurf (trifluridine and tipiracil)
Drug: Fruquintinib

First Posted Date: 2025-05-28

Last Posted Date: 2025-05-28

Lead Sponsor: Criterium, Inc.

Target Recruit Count: 120

Registration Number: NCT06992258

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Phase 2

Recruiting

Conditions: Breast Cancer
Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer

Interventions: Drug: Tucatinib
Drug: Eribulin
Drug: Trastuzumab

First Posted Date: 2022-07-14

Last Posted Date: 2025-01-13

Lead Sponsor: Criterium, Inc.

Target Recruit Count: 30

Registration Number: NCT05458674

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
George Washington Medical Faculty Associates, Washington, District of Columbia, United States
🇺🇸
New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States

and more 3 locations

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Phase 1

Recruiting

Conditions: HER2-positive Metastatic Breast Cancer

Interventions: Drug: Alpelisib
Drug: Tucatinib
Drug: Fulvestrant

First Posted Date: 2022-02-09

Last Posted Date: 2024-03-19

Lead Sponsor: Criterium, Inc.

Target Recruit Count: 40

Registration Number: NCT05230810

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
Cancer Care & Hematology-Fort Collins, Fort Collins, Colorado, United States
🇺🇸
Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States

and more 1 locations

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

Phase 1

Withdrawn

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: AMG 510
Drug: MVASI

First Posted Date: 2022-01-06

Last Posted Date: 2023-10-18

Lead Sponsor: Criterium, Inc.

Registration Number: NCT05180422

Locations: 🇺🇸
Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Abemaciclib
Drug: Elacestrant

First Posted Date: 2021-03-10

Last Posted Date: 2023-07-27

Lead Sponsor: Criterium, Inc.

Target Recruit Count: 44

Registration Number: NCT04791384

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Duke Cancer Center, Durham, North Carolina, United States
🇺🇸
Cancer Care Northwest, Spokane Valley, Washington, United States

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

Phase 1

Terminated

Conditions: Advanced Non-Small Cell Lung Cancer With MET Mutations

Interventions: Drug: Tepotinib

First Posted Date: 2021-02-04

Last Posted Date: 2023-10-18

Lead Sponsor: Criterium, Inc.

Target Recruit Count: 2

Registration Number: NCT04739358

Locations: 🇺🇸
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

and more 2 locations

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Adjuvant Therapy
Drug: Palbociclib
Drug: Fulvestrant

First Posted Date: 2020-09-28

Last Posted Date: 2025-01-13

Lead Sponsor: Criterium, Inc.

Target Recruit Count: 70

Registration Number: NCT04567420

Locations: 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 12 locations

FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Oxaliplatin

First Posted Date: 2019-11-19

Last Posted Date: 2023-07-27

Lead Sponsor: Criterium, Inc.

Target Recruit Count: 27

Registration Number: NCT04169347

Locations: 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

and more 5 locations

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

Phase 2

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: brigatinib

First Posted Date: 2016-03-11

Last Posted Date: 2023-01-26

Lead Sponsor: Criterium, Inc.

Target Recruit Count: 32

Registration Number: NCT02706626

Locations: 🇺🇸
University Of Colorado, Denver, Colorado, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
Vanderbilt Unversity Medical Center, Nashville, Tennessee, United States

and more 1 locations

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

Phase 2

Terminated

Conditions: Gastric Adenocarcinoma
Colorectal Adenocarcinoma
Pancreatic Adenocarcinoma
Cholangiocarcinoma
Hepatocellular Adenocarcinoma
Esophageal Adenocarcinoma

Interventions: Drug: ceritinib

First Posted Date: 2015-12-23

Last Posted Date: 2018-04-02

Lead Sponsor: Criterium, Inc.

Target Recruit Count: 4

Registration Number: NCT02638909

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
Yale University, Yale Cancer Center, New Haven, Connecticut, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy